Ipsen’s Group Strategy

Focus. Together. For patients & society. Ipsen’s new Group strategy explained

David Loew, CEO IpsenFive months ago, I joined Ipsen as CEO. I was excited to join a company with 90 years of patient service and consistent growth, and a clear mission, to prolong and improve patients’ lives and health outcomes.

Today, I have the pleasure of kicking off a new chapter in this long history of success. Following a thorough review of what makes us thrive and where we can improve, working closely together with the Executive Leadership Team and many more colleagues across the globe, we are presenting a new Group strategy for Ipsen.

In the coming years, we will build on our strong foundation of engaged employees, agile development capabilities and global commercial footprint to drive positive impact for patients, our people and our business. Our new Group strategy positions Ipsen for long-term success and can be summed up quite simply: Focus. Together. For patients & society.

Focus: A clear sense of prioritization will drive our activities. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience – areas where we have proven experience and global capabilities along with a strong network of partners. We will focus on maximizing our existing brands and strengthen and accelerate our external innovation efforts in clearly-defined segments, leveraging €3Bn in firepower over the next four years to replenish our innovative pipeline.

Together: Our employees are the hearts, brains and architects of our success. Our experienced, global team will work together to boost a culture of collaboration, patient-centricity and innovation, and we will hone our operational excellence to continue to be an employer of choice for highly engaged talent. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline.

For patients & society: We will deliver innovative treatments that make a real difference in patients’ daily lives and partner with the entire healthcare ecosystem to ensure they have access to them. By concentrating on the right priorities, we will create sustainable, long-term growth and positive impact for all stakeholders and most importantly for patients and society.

We’ve defined four strategic priorities to achieve these ambitious goals: bring the full potential of our innovative medicines to patients; build a high-value sustainable pipeline; deliver efficiencies to enable targeted investment & growth; boost culture of collaboration and excellence.

With this new strategy concentrating on the right priorities, I am confident we will realize our vision of being a leading global mid-size biopharmaceutical company, with a focus on transformative medicines in oncology, rare disease and neuroscience.

The next chapter in Ipsen’s storied history begins today – and I look forward to making it a reality in collaboration with our 5,700+ Ipsen colleagues and numerous partners across the world.

Group strategy

Bring the full potential of our innovative medicines to patients

Build a high-value sustainable pipeline

Deliver efficiencies to enable targeted & growth

Boost culture of collaboration & excellence

4 strategic priorities


We’re presenting a new analysis assessing treatment patterns of adults living with spasticity in a real-life setting at the virtual @ISPRM congress. Spasticity is a condition which is estimated to affect more than 12 million people worldwide. #Neuroscience https://t.co/u92AQuOHXX

Ahead of the virtual @ISPRM congress, hear Dr. @AndrLysandro, Ipsen, discuss how modern data-mining techniques are helping us better understand the medical journey and unmet needs of people living with spasticity, so we can help evolve standards of care. #Neuroscience https://t.co/BGOsei4OPM

At Ipsen, we continuously work to innovate in #Oncology, including in #RCC, the most common type of kidney cancer which often carries a significant disease burden. We are pleased to share some of our latest updates at #ASCO21. https://t.co/FaMBLXALP8

We are committed to supporting people living with hard-to-treat cancers. Those living with certain types of differentiated #thyroidcancer often have limited treatment options, and there is a pressing need for innovation. #Oncology https://t.co/m23NxyXAC7

Today is World Environment Day! Learn about our commitment to protecting biodiversity and how we’re working to preserve the planet for future generations here: https://t.co/8Ti4fkJOSY
#GenerationRestoration #WorldEnvironmentDay #Corporate https://t.co/zhh1kqe4lB

In 2020 alone, over 580,000 new cases of #thyroidcancer were diagnosed worldwide, making it the ninth most commonly occurring cancer globally. #ASCO21 is an opportunity for us to share our progress in #Oncology, focusing on cancers with high unmet medical needs. https://t.co/f9oX9IHMLE
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021